Moderna
MRNA
$132.70
Share price
2.82%
Change (1 day)
1.87%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
Moderna (MRNA) - Total debt
Total debt on the balance sheet as of March 2024 : $1.23 B
According to Moderna 's latest financial reports the company's total debt is $1.23 B. A company’s total debt is the sum of all current and non-current debts.
Moderna - Total debt on balance sheet (from 2017 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $1.24 B | 3.58% |
| 2022-12-31 | $1.20 B | 31% |
| 2021-12-31 | $0.91 B | 286.5% |
| 2020-12-31 | $0.23 B | 79.05% |
| 2019-12-31 | $0.13 B | 295.25% |
| 2018-12-31 | $33.48 M | 113.48% |
| 2017-12-31 | $15.68 M | 25.5% |
| 2016-12-31 | $12.5 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $33.63 B | 2,618.84% | 🇺🇸 USA |
 Novartis NVS | $27.28 B | 2,105.66% | 🇨🇭 Switzerland |
 Merck MRK | $35.05 B | 2,733.87% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | $2.38 M | -99.81% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Athersys ATHX | $18.57 M | -98.50% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $1.30 B | 5.19% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | $0.11 B | -90.41% | 🇺🇸 USA |